News Releases

Keyword Search

Nov-17-2020
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
Nov-17-2020
Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
Nov-11-2020
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting
Nov-09-2020
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
Nov-04-2020
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
Oct-06-2020
Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma
Sep-21-2020
Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
Sep-10-2020
Oncternal Therapeutics to Participate in September Investor Conferences
Aug-27-2020
Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million
Aug-27-2020
Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering